Advaxis, Inc. is a US-based biotech firm that specializes in discovering, developing, and selling Listeria monocytogenes (Lm) antigen delivery products. The company's focus is on creating therapies for multisectoral illnesses, including prostate cancer, NSCLC, HPV-linked cancer, and neoantigen-directed therapies. The company collaborates with several businesses, including Merck and OS Therapies, and was founded in 2002, based in New Jersey.